Biopharma and med-tech company deals and M&As: Abbott, Alvotech, Ambros, Amplitude, Avricore, Beyond Air, Bioarctic, BMS, Chai Discovery, Chong Kun Dang, Darmiyan ...
A compound targeting serotonin receptor 5-HT2A (5-HT2AR) signaling in the gut could activate antitumor immunity in colorectal cancer (CRC) and improve responses to immunotherapy without causing ...
Innovstone Therapeutics Ltd. has synthesized cathepsin C (dipeptidyl peptidase I; DPP-1) inhibitors found to be potentially useful for the treatment of autoimmune diseases and cancer.
An increase in the level of M&A activity and some sizeable financing rounds are encouraging signs for the med-tech investment environment, said Joey Mason, life sciences venture partner at Claret ...
Rinascera Therapeutics Inc. has secured enough initial funding to acquire two drugs for rare genetic skin diseases, despite stalled development with their previous owners. The company, whose name ...
Hansoh Pharmaceutical Group Co. Ltd. has taken a new step in the evolution of China’s “newco” strategy, combining its newly created U.S. company, Avere Therapeutics Inc., with Nasdaq-listed Nextcure ...
At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain barrier-penetrant AAV9 gene therapy ...
BioWorld - Sunday, August 30, 2026 Breaking News: Best of BioWorld Science: Q2 See today's BioWorld Science Home » BioWorld Science » Nampt inhibitors reported in Alphina Therapeutics patent To read ...
Astrazeneca plc has added a dual PDE3/4 inhibitor candidate to its chronic obstructive pulmonary disease (COPD) portfolio via a deal worth up to $2.1 billion with Chia Tai Tianqing Pharmaceutical ...
Takeda Pharmaceutical Co. Ltd.’s anti-CD38 antibody mezagitamab (TAK-079) is showing benefits beyond platelet restoration, with new data suggesting the candidate may improve quality of life for ...
Arnatar Therapeutics Inc. has received clinical trial clearance from China’s National Medical Products Administration (NMPA) for ART-5, a potential first-in-class upregulating antisense ...
The gene therapy specialist formerly known as EG427 has a new name and fresh momentum, after closing a €33 million (US$37.7 million) series C that will further advance clinical development of the lead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results